Wellcome Pharmaceuticals launches Phase II clinical trials of class 2.3 new drugs

Silver drop pills are one of the leading products of Wellcome Pharmaceuticals with invention patents and core technology, composed of gold and silver flowers and jaundice chinese medicine, with the effect of clearing heat, detoxifying, anti-inflammatory, for acute and chronic tonsillitis, acute and chronic pharyngitis, upper respiratory tract infections.
the goal of this Phase II clinical trial project is to add the new functional treatment of "recurring mouth ulcers" on the basis of the original approved functional treatment.
Wellcome Pharmaceuticals said that the project in January 2018 obtained the State Drug Administration (formerly the State Food and Drug Administration) drug clinical trial approval (batch number: 2018L02064), according to the approval opinion, the company determined the clinical research program, in November 2020 to complete phase II clinical trial project;
preclinical results show that silver yellow drops have obvious therapeutic effect on the oral ulcers of rabbits caused by Staphylococcus auspicrus, and also have obvious therapeutic effect on the mouth ulcers of rabbits caused by chemical burns.
phase II clinical trials of the project are progressing in an orderly manner.